NEW YORK/GENEVA, JULY 6, 2020—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes Johnson & Johnson’s (J&J) announcement today to reduce the price of its tuberculosis (TB) drug bedaquiline to $1.50 per day. Governments must now urgently scale up the use of the treatment as a core part of drug-resistant TB (DR-TB) regimens, MSF said.
The World Health Organization (WHO) recommends the easier-to-adhere-to bedaquiline—sold by J&J as Sirturo—as the backbone of DR-TB treatment. The oral medicine can replace older, more toxic drugs that have to be injected daily and can cause intolerable side effects, such as deafness. However, the price charged by J&J for bedaquiline has remained a critical barrier to countries that want to scale up this lifesaving treatment, especially considering the drug is just one of many required in a DR-TB treatment regimen.
“With a reduced price, governments must urgently scale-up the use of bedaquiline as a core part of all-oral DR-TB regimens,” said Dr. Pilar Ustero, TB advisor at MSF’s Access Campaign. “Let’s not waste a minute putting an end to the suffering of people with DR-TB.”
In light of the COVID-19 pandemic, WHO has further advised countries to treat people with DR-TB in the safety of their homes by using all-oral regimens, including bedaquiline, instead of injections that require people to go to clinics, where they could possibly be exposed to other patients who have contracted the novel coronavirus. The older, longer DR-TB treatment used by many countries up to now required people to take up to 14,000 pills over the course of nearly two years, and to endure up to eight months of painful daily injections.
“As the world reels from the COVID-19 pandemic, access to affordable treatment with bedaquiline is the need of the hour for people with DR-TB,” Ustero said. “Not only are the older drugs that have to be injected painful and can cause severe side effects, they also require people to travel to health facilities every day, putting them at increased risk of COVID-19 infection.”
Given the substantial taxpayer funding J&J received for bedaquiline’s research and development in the United States and other countries, MSF and others have been calling for the corporation to lower the price to increase access to the drug. A study conducted by researchers at Liverpool University showed that bedaquiline could be produced and sold at profit for as little as $0.25 per day.
“J&J didn’t develop this drug alone,” said Sharonann Lynch, senior HIV & TB advisor for MSF’s Access Campaign. “Bedaquiline was developed with considerable taxpayer, non-profit and philanthropic support. J&J received public investments in the hundreds of millions of dollars, including grants from the U.S. government and various financial incentives. Treatment providers such as MSF also contributed to research on the drug. J&J should not be charging high prices for this drug anywhere.”
While the newly-reduced price is 32 percent lower—based on the previous price of $400 for a six-month treatment course—than the previous lowest price, it is only available to a list of countries determined by J&J and tied to purchase commitments made through the Global Drug Facility (GDF), an organization run by the Stop TB Partnership that supplies TB drugs to low- and middle-income countries. Countries that do not purchase from the GDF are not eligible for the lower price and continue to face higher prices charged by J&J, or from its Russian commercial partner Pharmstandard for some countries in the Commonwealth of Independent States. For example, the Russian Federation pays more than $8 per day for bedaquiline, which is significantly higher than the price available now to countries eligible for the reduced price of $1.50 per day.
J&J should further reduce the price and offer the lower price to all countries with a high DR-TB burden so more lives can be saved, MSF said.
This is even more critical as J&J is currently the sole manufacturer of bedaquiline and has patented the drug in most countries, which means it controls the price at which the drug is sold and blocks more affordable generic versions from being made available. For example, J&J’s monopoly blocks other manufacturers in India and elsewhere from producing and supplying more affordable generic versions. While the corporation’s patent on the base compound of bedaquiline expires in 2023, it has resorted to “patent evergreening” by filing additional patents to extend its patent monopoly on the drug to 2027 in many TB-affected countries. Generic manufacturers say they are able to produce more affordable versions starting in 2021 but are blocked from entering the market by J&J’s patent. MSF has been calling on J&J not to enforce its patents on bedaquiline and cease its efforts to prolong its monopoly through patent extensions that would further delay the availability of quality-assured generic versions of the drug.
MSF has been pressuring J&J to lower the price of bedaquiline since it came to market in 2012. Last year, MSF launched a global campaign alongside people living with TB, activists, and civil society members urging J&J to cut by more than half the price it charges for the drug in low- and some middle-income countries to $1 per day. More than 120,700 people signed petitions calling on J&J to drop the price.
“We’ve protested outside of J&J’s global headquarters and its offices around the world, alongside people who have survived TB and its painful, arduous treatment, urging the corporation to drop the price of this lifesaving drug,” said Lara Dovifat, campaigns and advocacy advisor at MSF’s Access Campaign. “While we anxiously wait for more affordable generic versions of bedaquiline to become available, we want to urge governments to make sure their people with DR-TB get today’s best-possible treatment, and today’s price reduction is a helpful step.”
MSF is the largest non-governmental provider of TB treatment worldwide and has been involved in TB care for 30 years, often working alongside national health authorities to treat people in a wide variety of settings, including chronic conflict zones, urban slums, prisons, refugee camps, and rural areas. As of September 2019, across MSF projects in 14 countries, more than 2,000 people have been treated with the newer TB drugs bedaquiline and delamanid, including 1,517 with bedaquiline, 429 with delamanid, and 429 with a combination of both medicines. Globally, an estimated 484,000 people developed DR-TB in 2018, but only 32 percent were treated.